Progenitor Cell Therapy, LLC (“PCT”), our wholly-owned subsidiary, is an internationally recognized contract development and manufacturing organization (CDMO) focused on providing exceptional service, quality and value to its clients, which include an expanding range of development stage organizations, Fortune 500 biotechnology, pharmaceutical and medical product companies, as well as leading academic research institutions.
PCT’s expert, customer-centric services include current Good Manufacturing Practices/Good Laboratory Practices (“cGMP/GLP”) manufacturing; engineering and innovation; product, process and assay development; Good Tissue Practices (“GTP”) cell and tissue processing; cell and tissue sourcing and banking; distribution and delivery; and consulting and regulatory services.
PCT operates two state-of-the-art, accredited and certified U.S. facilities, one in Allendale, New Jersey and the other in Mountain View, California and is looking to expand its service activities both in the U.S. and into Europe during 2014.
Advantage of Supporting Clients from Bench to Bedside
PCT is an industry leader in contract development and manufacture of cell therapy products. With more than 15 years of exclusive cell therapy-focused experience, PCT helps its clients bridge the gap between discovery and patient care by turning concepts in the cell therapy industry into clinical practice.
PCT helps clients reduce the risks of product development and shorten the time it takes to receive regulatory approval; and provides custom, on demand services to reduce the overall costs of clinical development programs.
PCT has a proven track record of success. In fact, PCT is the only CDMO to see a client’s cell therapy product receive approval from the FDA for commercial sale.
To learn more, please visit www.pctcelltherapy.com